193 related articles for article (PubMed ID: 16223973)
1. SOM230 inhibits insulin-like growth factor-I action in mammary gland development by pituitary independent mechanism: mediated through somatostatin subtype receptor 3?
Ruan W; Fahlbusch F; Clemmons DR; Monaco ME; Walden PD; Silva AP; Schmid HA; Kleinberg DL
Mol Endocrinol; 2006 Feb; 20(2):426-36. PubMed ID: 16223973
[TBL] [Abstract][Full Text] [Related]
2. SOM230: a new somatostatin peptidomimetic with potent inhibitory effects on the growth hormone/insulin-like growth factor-I axis in rats, primates, and dogs.
Weckbecker G; Briner U; Lewis I; Bruns C
Endocrinology; 2002 Oct; 143(10):4123-30. PubMed ID: 12239124
[TBL] [Abstract][Full Text] [Related]
3. Short- and long-term effects of octreotide and SOM230 on GH, IGF-I, ACTH, corticosterone and ghrelin in rats.
Schmid HA; Silva AP
J Endocrinol Invest; 2005; 28(11 Suppl International):28-35. PubMed ID: 16625842
[TBL] [Abstract][Full Text] [Related]
4. The novel somatostatin ligand (SOM230) regulates human and rat anterior pituitary hormone secretion.
Murray RD; Kim K; Ren SG; Lewis I; Weckbecker G; Bruns C; Melmed S
J Clin Endocrinol Metab; 2004 Jun; 89(6):3027-32. PubMed ID: 15181094
[TBL] [Abstract][Full Text] [Related]
5. SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile.
Bruns C; Lewis I; Briner U; Meno-Tetang G; Weckbecker G
Eur J Endocrinol; 2002 May; 146(5):707-16. PubMed ID: 11980628
[TBL] [Abstract][Full Text] [Related]
6. Pre-clinical and clinical experiences with novel somatostatin ligands: advantages, disadvantages and new prospects.
Hofland LJ; van der Hoek J; Feelders R; van der Lely AJ; de Herder W; Lamberts SW
J Endocrinol Invest; 2005; 28(11 Suppl International):36-42. PubMed ID: 16625843
[TBL] [Abstract][Full Text] [Related]
7. The somatostatin analogue SOM230, compared with octreotide, induces differential effects in several metabolic pathways in acromegalic patients.
van der Hoek J; van der Lelij AJ; Feelders RA; de Herder WW; Uitterlinden P; Poon KW; Boerlin V; Lewis I; Krahnke T; Hofland LJ; Lamberts SW
Clin Endocrinol (Oxf); 2005 Aug; 63(2):176-84. PubMed ID: 16060911
[TBL] [Abstract][Full Text] [Related]
8. Estradiol enhances the stimulatory effect of insulin-like growth factor-I (IGF-I) on mammary development and growth hormone-induced IGF-I messenger ribonucleic acid.
Ruan W; Catanese V; Wieczorek R; Feldman M; Kleinberg DL
Endocrinology; 1995 Mar; 136(3):1296-302. PubMed ID: 7867584
[TBL] [Abstract][Full Text] [Related]
9. Effects of somatostatin analogs on glucose homeostasis in rats.
Schmid HA; Brueggen J
J Endocrinol; 2012 Jan; 212(1):49-60. PubMed ID: 21987782
[TBL] [Abstract][Full Text] [Related]
10. Growth hormone suppresses the expression of IGFBP-5, and promotes the IGF-I-induced phosphorylation of Akt in bovine mammary epithelial cells.
Sakamoto K; Yano T; Kobayashi T; Hagino A; Aso H; Obara Y
Domest Anim Endocrinol; 2007 May; 32(4):260-72. PubMed ID: 16698222
[TBL] [Abstract][Full Text] [Related]
11. Pasireotide, an IGF-I action inhibitor, prevents growth hormone and estradiol-induced mammary hyperplasia.
Kleinberg DL; Ameri P; Singh B
Pituitary; 2011 Mar; 14(1):44-52. PubMed ID: 20890664
[TBL] [Abstract][Full Text] [Related]
12. The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro.
Hofland LJ; van der Hoek J; van Koetsveld PM; de Herder WW; Waaijers M; Sprij-Mooij D; Bruns C; Weckbecker G; Feelders R; van der Lely AJ; Beckers A; Lamberts SW
J Clin Endocrinol Metab; 2004 Apr; 89(4):1577-85. PubMed ID: 15070915
[TBL] [Abstract][Full Text] [Related]
13. Evidence that the mammary fat pad mediates the action of growth hormone in mammary gland development.
Walden PD; Ruan W; Feldman M; Kleinberg DL
Endocrinology; 1998 Feb; 139(2):659-62. PubMed ID: 9449638
[TBL] [Abstract][Full Text] [Related]
14. Octreotide inhibits insulin-like growth factor-I hepatic gene expression in the hypophysectomized rat: evidence for a direct and indirect mechanism of action.
Serri O; Brazeau P; Kachra Z; Posner B
Endocrinology; 1992 Apr; 130(4):1816-21. PubMed ID: 1547711
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic-pharmacodynamic comparison of a novel multiligand somatostatin analog, SOM230, with octreotide in patients with acromegaly.
Ma P; Wang Y; van der Hoek J; Nedelman J; Schran H; Tran LL; Lamberts SW
Clin Pharmacol Ther; 2005 Jul; 78(1):69-80. PubMed ID: 16003295
[TBL] [Abstract][Full Text] [Related]
16. Role of prolactin, growth hormone and insulin-like growth factor 1 in mammary gland involution in the dairy cow.
Accorsi PA; Pacioni B; Pezzi C; Forni M; Flint DJ; Seren E
J Dairy Sci; 2002 Mar; 85(3):507-13. PubMed ID: 11949853
[TBL] [Abstract][Full Text] [Related]
17. The somatostatin analog octreotide inhibits GH-stimulated, but not IGF-I-stimulated, bone growth in hypophysectomized rats.
Zapf J; Gosteli-Peter M; Weckbecker G; Hunziker EB; Reinecke M
Endocrinology; 2002 Aug; 143(8):2944-52. PubMed ID: 12130560
[TBL] [Abstract][Full Text] [Related]
18. Somatostatin receptors in non-neuroendocrine malignancies: the potential role of somatostatin analogs in solid tumors.
Hasskarl J; Kaufmann M; Schmid HA
Future Oncol; 2011 Jul; 7(7):895-913. PubMed ID: 21732759
[TBL] [Abstract][Full Text] [Related]
19. Insulin-like growth factor binding proteins initiate cell death and extracellular matrix remodeling in the mammary gland.
Flint DJ; Boutinaud M; Tonner E; Wilde CJ; Hurley W; Accorsi PA; Kolb AF; Whitelaw CB; Beattie J; Allan GJ
Domest Anim Endocrinol; 2005 Aug; 29(2):274-82. PubMed ID: 15998501
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of insulin-like growth factor signaling pathways in mammary gland by pure antiestrogen ICI 182,780.
Chan TW; Pollak M; Huynh H
Clin Cancer Res; 2001 Aug; 7(8):2545-54. PubMed ID: 11489838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
